AHA: Inclisiran Twice Yearly May Effectively Control Cholesterol

This article originally appeared here.
Share this content:
AHA: Inclisiran Twice Yearly May Effectively Control Cholesterol
AHA: Inclisiran Twice Yearly May Effectively Control Cholesterol

TUESDAY, Nov. 15, 2016 (HealthDay News) -- A new injectable medication called inclisiran cuts low-density lipoprotein (LDL) cholesterol by half or more, and the effect could last for four to six months, according to research presented at the annual meeting of the American Heart Association, held from Nov. 12 to 16 in New Orleans.

Inclisiran is a next-level PCSK9 inhibitor, which works on a genetic level to prevent cells from producing PCSK9, study presenter Kausik Ray, M.D., of Imperial College London, told HealthDay. The inclisiran clinical trial involved 501 patients who were assigned to either a control group or one of four groups that received different doses of the drug.

One dose of inclisiran at 300 mg or greater caused a 51 percent drop in LDL cholesterol that lasted at least 90 days, while two doses caused a 57 percent reduction that lasted up to six months, Ray reported. Based on these results, Ray and his colleagues estimate patients would only need an inclisiran injection two or three times a year to control their cholesterol.

Side effects from the medication were similar to those reported by patients taking either statins or placebos, the researchers reported. Muscle aches, headache, fatigue, back pain, high blood pressure, diarrhea, and dizziness were the most common side effects.

The study was funded by The Medicines Company, the manufacturer of inclisiran.

Abstract
More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

60 Percent of Adults Report Adverse Childhood Experiences

>60 Percent of Adults Report Adverse Childhood Experiences

Higher ACE exposures for black, Hispanic, multiracial individuals, those with below high school education

Few Yogurt Products Qualify As Low-Sugar

Few Yogurt Products Qualify As Low-Sugar

Only two of 101 children's yogurt and fromage frais products had ≤5 g sugar/100 g of product

Allopurinol Dose Escalation for Gout Doesn't Improve Mortality

Allopurinol Dose Escalation for Gout Doesn't Improve Mortality

Linked to small increase in mortality; at 2 years, 31 percent of dose escalators achieved serum urate goal

is free, fast, and customized just for you!




Already a member?

Sign In Now »